Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C12H18N2O7 |
| Molecular Weight | 302.2805 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@](O)(CO)[C@H](O)[C@@]12NC(=O)[C@@](O)(NC1=O)C(=C)CCO2
InChI
InChIKey=WOUDXEYYJPOSNE-VKZDFBPFSA-N
InChI=1S/C12H18N2O7/c1-6-3-4-21-12(7(16)10(2,19)5-15)9(18)13-11(6,20)8(17)14-12/h7,15-16,19-20H,1,3-5H2,2H3,(H,13,18)(H,14,17)/t7-,10-,11+,12-/m0/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/16181146
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16181146
Bicyclomycin has been used to treat diarrhea in humans and bacterial diarrhea in calves and pigs and is marketed by Fujisawa (Osaka, Japan) under the trade name Bicozamycin. This drug is the selective inhibitor of rho, a member of the RecA-type ATPase class of enzymes that use nucleotide contacts to couple oligonucleotide translocation to ATP hydrolysis.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3965336
None of the 11 subjects given bicozamycin orally for 3 wk at a dosage of 500 mg four times a day developed diarrhea as compared with an incidence of 53% diarrhea (10 of 19 subjects) in the placebo group (p = 0.003).
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
180516
Created by
admin on Wed Apr 02 09:33:27 GMT 2025 , Edited by admin on Wed Apr 02 09:33:27 GMT 2025
|
PRIMARY | |||
|
4356
Created by
admin on Wed Apr 02 09:33:27 GMT 2025 , Edited by admin on Wed Apr 02 09:33:27 GMT 2025
|
PRIMARY | |||
|
100000085900
Created by
admin on Wed Apr 02 09:33:27 GMT 2025 , Edited by admin on Wed Apr 02 09:33:27 GMT 2025
|
PRIMARY | |||
|
CHEMBL2103766
Created by
admin on Wed Apr 02 09:33:27 GMT 2025 , Edited by admin on Wed Apr 02 09:33:27 GMT 2025
|
PRIMARY | |||
|
253-795-3
Created by
admin on Wed Apr 02 09:33:27 GMT 2025 , Edited by admin on Wed Apr 02 09:33:27 GMT 2025
|
PRIMARY | |||
|
C024504
Created by
admin on Wed Apr 02 09:33:27 GMT 2025 , Edited by admin on Wed Apr 02 09:33:27 GMT 2025
|
PRIMARY | |||
|
65807
Created by
admin on Wed Apr 02 09:33:27 GMT 2025 , Edited by admin on Wed Apr 02 09:33:27 GMT 2025
|
PRIMARY | |||
|
SUB05822MIG
Created by
admin on Wed Apr 02 09:33:27 GMT 2025 , Edited by admin on Wed Apr 02 09:33:27 GMT 2025
|
PRIMARY | |||
|
Bicyclomycin
Created by
admin on Wed Apr 02 09:33:27 GMT 2025 , Edited by admin on Wed Apr 02 09:33:27 GMT 2025
|
PRIMARY | |||
|
38129-37-2
Created by
admin on Wed Apr 02 09:33:27 GMT 2025 , Edited by admin on Wed Apr 02 09:33:27 GMT 2025
|
PRIMARY | |||
|
C90933
Created by
admin on Wed Apr 02 09:33:27 GMT 2025 , Edited by admin on Wed Apr 02 09:33:27 GMT 2025
|
PRIMARY | |||
|
J03U9E2P82
Created by
admin on Wed Apr 02 09:33:27 GMT 2025 , Edited by admin on Wed Apr 02 09:33:27 GMT 2025
|
PRIMARY | |||
|
DTXSID8042636
Created by
admin on Wed Apr 02 09:33:27 GMT 2025 , Edited by admin on Wed Apr 02 09:33:27 GMT 2025
|
PRIMARY | |||
|
60584
Created by
admin on Wed Apr 02 09:33:27 GMT 2025 , Edited by admin on Wed Apr 02 09:33:27 GMT 2025
|
PRIMARY | |||
|
m2477
Created by
admin on Wed Apr 02 09:33:27 GMT 2025 , Edited by admin on Wed Apr 02 09:33:27 GMT 2025
|
PRIMARY | Merck Index |
ACTIVE MOIETY